AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1451930
Drug: cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefuroxime axetil 500 mg/day (n = 51)
Trial: 1451930
Drug: cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefuroxime axetil 1000 mg/day (n = 4)
Trial: 6089581
Drug: Beta‐adrenoceptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐adrenoceptor blocker propranolol (160 mg/day)
Trial: 29906310
Drug: Every-8-hour vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every-8-hour vancomycin dosing
Trial: 29906310
Drug: Every-8-hour cefepime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every-8-hour cefepime dosing
Trial: 29906310
Drug: Every-12-hour vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every-12-hour vancomycin dosing
Trial: 29906310
Drug: Every-12-hour cefepime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every-12-hour cefepime dosing
Trial: 18428198
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel plus high-dose calcitriol
Trial: 16147846
Drug: Intramuscular benzathine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathine penicillin G suspension (Bicillin L‐A), 2.4 million units
Trial: 1308263
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in young females
Trial: 1308263
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in older females
Trial: 1308263
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in both age groups
Trial: 6730871
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia + epidural analgesia (local anaesthetics + morphine) continued for 72 h
Trial: 15730434
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg) and herbal ephedra (20 mg ephedrine)
Trial: 10908688
Drug: Homeopathic gel
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic gel
Trial: 1462402
Drug: Diltiazem (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (n = 12, 240-360 mg)
Trial: 1462402
Drug: Verapamil (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (n = 12, 240-360 mg)
Trial: 3931216
Drug: misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol 200 micrograms daily
Trial: 3931216
Drug: misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 800 micrograms daily
Trial: 3931216
Drug: cimetidine 1200
RxNorm normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 1200 mg daily
Trial: 18325056
Drug: Darifenacin controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin controlled-release 7.5 mg
Trial: 18325056
Drug: Darifenacin controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin controlled-release 15 mg
Trial: 12466781
Drug: Atropine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.5 mg) administered to patients showing signs of fatigue before reaching minimal HR (group A)
Trial: 10728909
Drug: Intravenous etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous etoposide 150 mg/M2
Trial: 10728909
Drug: Intravenous etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous etoposide 150 mg/M2 with mannitol 15 gm/M2
Trial: 7493659
Drug: Dairy foods
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy foods group (n = 81) consuming approximately 30 grams of dairy protein daily
Trial: 6787694
Drug: Intravenous pirenzepine
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pirenzepine 10 mg
Trial: 28931011
Drug: Central information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central information highlighting flaws in the expert’s message (e.g., quality of the research presented by the expert)
Trial: 28931011
Drug: Peripheral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral information about the expert (e.g., credentials)
Trial: 12919340
Drug: Antiepileptic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic treatments
Trial: 10675381
Drug: ATP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP treatment (10 intravenous 30-hour infusions at 2- to 4-week intervals)
Trial: 10086544
Drug: Aprotinin therapy
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin therapy
Trial: 8121306
Drug: Lipid-heparin infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-heparin infusion (Control)
Trial: 8121306
Drug: Lipid-heparin infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-heparin infusion (Control) + Arginine (ARG)
Trial: 26125769
Drug: emergency PCI
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emergency PCI + rhBNP early treatment (Group B)
Trial: 26125769
Drug: emergency PCI
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emergency PCI + late rhBNP treatment (Group C)
Trial: 24299712
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation (1.6 × 10(8) colony-forming units of LPR/capsule, 2 capsules per day)
Trial: 22990514
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient therapy including mechanical lymph drainage using the RAGodoy® apparatus for 6 to 8 hours daily, Godoy & Godoy cervical stimulation technique for 20 minutes per day, and manual lymph drainage for one hour.
Trial: 11334123
Drug: Montelukast (Cys-LT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (Cys-LT1 antagonist)
Trial: 2421622
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) therapy for 1 week
Trial: 2421622
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) therapy
Trial: 29411446
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) during hospitalisation
Trial: 29411446
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) post-discharge
Trial: 29411446
Drug: NRT use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT use during hospitalisation for those using six or more medications
Trial: 24723432
Drug: venlafaxine Extended‐Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine Extended‐Release (XR) treatment
Trial: 22178393
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg orally administered hydrocortisone
Trial: 17363530
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (0.125 or 0.250 mg/kg), bortezomib (0.7, 1.0, or 1.3 mg/m(2)), ascorbic acid (1 g) i.v. on days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles.
Trial: 17363530
Drug: Bortezomib (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (0.7 mg/m(2))
Trial: 17363530
Drug: Bortezomib (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.0 or 1.3 mg/m(2))
Trial: 15784480
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299v (ProViva) in addition to conventional therapy (treatment group, n = 52)
Trial: 15784480
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy alone (control group, n = 51)
Trial: 7615313
Drug: MkII implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MkII implant
Trial: 7615313
Drug: Standard Brånemark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Brånemark System implant
Trial: 2262234
Drug: MPA-L (methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA-L (methyl prednisolone acetate with lidocaine)
Trial: 23180154
Drug: α‐Lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐Lipoic acid (1,200 mg d(‐1) for 10 days)
Trial: 18793232
Drug: Muscular counterpulsation
RxNorm normalized name: Orchis mascula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscular counterpulsation (MCP) treatment for 30 minutes daily for the first eight postoperative days in addition to standard therapy.
Trial: 18793232
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative treatment without counterpulsation (control group).
Trial: 17382730
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus boosters
Trial: 11573587
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml(-1) with glucose 8 mg ml(-1)
Trial: 11573587
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml(-1) with glucose 80 mg ml(-1)
Trial: 1215448
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg/70 kg)
Trial: 7821012
Drug: Afterwork emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afterwork emollient cream
Trial: 7821012
Drug: No cream
RxNorm normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No cream (controls)
Trial: 31563660
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (20 g/day for 1 week, then 5 g/day for 7 weeks)
Trial: 31537373
Drug: Multivitamin multimineral
RxNorm normalized name: Multivitamin multimineral supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin multimineral supplement
Trial: 28130378
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with the NOAC apixaban
Trial: 28130378
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) therapy
Trial: 24448329
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 220 mg daily
Trial: 20234136
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg betamethasone in a single dose (group 2)
Trial: 18359663
Drug: PEG-IFN alpha-2b
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN alpha-2b treatment
Trial: 12823591
Drug: Lamivudine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (150 mg/day) for 104 weeks
Trial: 12823591
Drug: Lamivudine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (150 mg/day) for 104 weeks with or without 4 months of interferon (IFN) combination
Trial: 9010561
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy with modified phleum pratense allergenic extracts
Trial: 9010561
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not treated with specific IT, only with drugs)
Trial: 1379739
Drug: Glycosaminoglycan polysulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosaminoglycan polysulfate (600 LRU daily for 24 weeks)
Trial: 6360832
Drug: Calcium-vitamin-D-combination (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin-D-combination (single dose ampoules for peroral application)
Trial: 29989855
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (ABVD and BEACOPPescalated)
Trial: 19423614
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg daily for 7-10 days
Trial: 19423614
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 7-10 days
Trial: 17637587
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam 0.035 mg/kg (Group A)
Trial: 17637587
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam 0.035 mg/kg (Group C)
Trial: 17637587
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam 0.035 mg/kg (Group D)
Trial: 16085789
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 mg-10 mg/day; mean: 5.2 mg/day)
Trial: 16085789
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 mg-2 mg/day; mean: 1.0 mg/day)
Trial: 12376586
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 300 mg/d for 26 weeks, increased to 400 mg/d if <5% weight loss at week 12
Trial: 7850924
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) administered via intravenous infusion or oral administration
Trial: 2262487
Drug: Prophylactic CNS
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic CNS therapy (St. Jude regimen)
Trial: 2262487
Drug: Prophylactic CNS
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic CNS therapy (other regimens)
Trial: 2262487
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic CNS therapy
Trial: 19365010
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of tadalafil
Trial: 17039333
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (0.52 mmol/kg/day in four doses)
Trial: 14507122
Drug: Massage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage with music therapy
Trial: 14507122
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy only
Trial: 8458056
Drug: Aztreonam regimen
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam regimen (2 gm every 8 hours) plus clindamycin (600 to 900 mg q8h) or nafcillin (1.5 gm to 2 gm every 6 hours)
Trial: 8458056
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (aminoglycoside) including amikacin (5 mg/kg q8h) plus cefazolin (1 gm q8h) or amikacin (500 mg every 12 hours) plus mezlocillin (4 gm q6h) or tobramycin plus ticarcillin (3 gm to 4 gm q4h)
Trial: 2429619
Drug: Regimen PMP
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen PMP (CDDP 60 mg/m2, d 1, MMC 6 mg/m2, d 3, d 10 and PEP 5 mg/m2, d 3-7)
Trial: 2429619
Drug: Regimen PM
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen PM (CDDP 60 mg/m2, d 1 and MMC 6 mg/m2, d 3, d 10)
Trial: 2429619
Drug: Regimen PMF
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen PMF (CDDP 60 mg/m2, d 1, MMC 6 mg/m2, d 3, d 10 and FT 800 mg/body, d 3-21)
Trial: 26642949
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: two intra‐articular sacroiliac injections of local anaesthetic/corticosteroid guided by ultrasound in 7 days
Trial: 20968017
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy via the LGN‐222 quartz installation
Trial: 29889239
Drug: Artesunate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (2 mg/kg/day for 5 days)
Trial: 29889239
Drug: Chloroquine-primaquine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine-primaquine (0.5 mg/kg/day for 14 days)
Trial: 24378018
Drug: RDT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDT and drugs stock-out
Trial: 20881066
Drug: Betahistine 48
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 48 mg/d
Trial: 20881066
Drug: Betahistine 96
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 96 mg/d
Trial: 20881066
Drug: Betahistine 144
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 144 mg/d
Trial: 20881066
Drug: Betahistine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (all doses)
Trial: 10745254
Drug: G-CSF (D5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (D5 to D14)
Trial: 10745254
Drug: GM-CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF plus G-CSF (D5-D14 and D10-D14 respectively)
Trial: 8694202
Drug: Hydroxyethylstarch solution
RxNorm normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylstarch solution 10% (n=15)
Trial: 8694202
Drug: Pentoxifylline continuously
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline continuously (1.2 mg.kg-1.h-1) (n=15)
Trial: 1286500
Drug: Flumazenil (0.84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.84 mg IV, range: 0.2 mg to 1 mg)
Trial: 26787366
Drug: Citrus aurantium
RxNorm normalized name: Citrus aurantium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus aurantium essential oil through inhalation
Trial: 10475411
Drug: Antegrade/retrograde cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antegrade/retrograde cold blood cardioplegia with topical cooling (group II, n = 40)
Trial: 10475411
Drug: Antegrade crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antegrade crystalloid cardioplegia with topical cooling (group III, n = 41)
Trial: 8622020
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (FAC: fluorouracil 600 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 600 mg/m2)
Trial: 27743126
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg midazolam (Midazolam Group)
Trial: 19237920
Drug: Transfusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion of packed red blood cells at thresholds of 8, 9, or 10 g/dL
Trial: 15024332
Drug: Etidronate 200
RxNorm normalized name: etidronate 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 200 mg/day for 2 weeks, then 9-week intermission, followed by 2 weeks of etidronate
Trial: 8986484
Drug: Routine chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine chest physiotherapy (RCP) combined with oxygen administration via nasal cannula for 10 min